MedTrace Logo

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

NCT00387738 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 738

Last updated 2019-04-16

No results posted yet for this study

Summary

The purpose of this study is to find out if a new investigational vaccine, TOLAMBA™, is safe and effective in reducing the symptoms of ragweed allergy.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

BIOLOGICAL

Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate

Escalating doses, 6 weekly subcutaneous (under the skin) injections

BIOLOGICAL

Histamine base

Escalating doses, 6 weekly subcutaneous (under the skin) injections

Sponsors & Collaborators

  • Dynavax Technologies Corporation

    lead INDUSTRY

Principal Investigators

  • Eduardo Martins, MD, DPhil · Dynavax Technologies Corporation

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2007-05-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00387738 on ClinicalTrials.gov